NO2721243T3 - - Google Patents
Info
- Publication number
- NO2721243T3 NO2721243T3 NO12801069A NO12801069A NO2721243T3 NO 2721243 T3 NO2721243 T3 NO 2721243T3 NO 12801069 A NO12801069 A NO 12801069A NO 12801069 A NO12801069 A NO 12801069A NO 2721243 T3 NO2721243 T3 NO 2721243T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462058316P | 2014-10-01 | 2014-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2721243T3 true NO2721243T3 (he) | 2018-10-20 |
Family
ID=53784023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO12801069A NO2721243T3 (he) | 2014-10-01 | 2012-06-14 |
Country Status (33)
Country | Link |
---|---|
EP (4) | EP3089979B1 (he) |
JP (4) | JP6462865B2 (he) |
KR (2) | KR101921436B1 (he) |
CN (3) | CN114957255A (he) |
AR (1) | AR101367A1 (he) |
AU (3) | AU2015324530B2 (he) |
CA (1) | CA2963395C (he) |
CL (1) | CL2017000712A1 (he) |
CO (1) | CO2017003833A2 (he) |
CY (2) | CY1119678T1 (he) |
DK (2) | DK3293186T3 (he) |
EA (1) | EA031590B1 (he) |
ES (3) | ES2655884T3 (he) |
HR (2) | HRP20171950T1 (he) |
HU (2) | HUE052812T2 (he) |
IL (2) | IL251434B (he) |
LT (2) | LT3089979T (he) |
MA (1) | MA40123A1 (he) |
MX (2) | MX2017003695A (he) |
MY (1) | MY183987A (he) |
NO (1) | NO2721243T3 (he) |
PE (2) | PE20210922A1 (he) |
PH (2) | PH12017500580A1 (he) |
PL (1) | PL3089979T3 (he) |
PT (2) | PT3293186T (he) |
RS (2) | RS56786B1 (he) |
SG (2) | SG11201702576QA (he) |
SI (2) | SI3089979T1 (he) |
TN (2) | TN2017000112A1 (he) |
TW (3) | TWI692478B (he) |
UY (1) | UY36244A (he) |
WO (1) | WO2016053455A1 (he) |
ZA (1) | ZA201702478B (he) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
NO2760821T3 (he) | 2014-01-31 | 2018-03-10 | ||
CN110845498B (zh) * | 2014-01-31 | 2023-02-17 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
WO2016036893A1 (en) | 2014-09-04 | 2016-03-10 | Bristol-Myers Squibb Company | Diamide macrocycles that are fxia inhibitors |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
ES2761774T3 (es) | 2014-10-01 | 2020-05-21 | Merck Patent Gmbh | Derivados del ácido borónico |
NO2721243T3 (he) * | 2014-10-01 | 2018-10-20 | ||
JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JP6742348B2 (ja) | 2015-06-19 | 2020-08-19 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害剤としてのジアミド大員環 |
ES2871111T3 (es) | 2015-07-29 | 2021-10-28 | Bristol Myers Squibb Co | Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático |
CN107849026B (zh) * | 2015-07-29 | 2021-01-01 | 百时美施贵宝公司 | 携带烷基或环烷基p2′部分的因子xia大环抑制剂 |
JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
US10752641B2 (en) | 2016-03-02 | 2020-08-25 | Bristol-Myers Squibb Company | Diamide macrocycles having factor XIa inhibiting activity |
CR20180496A (es) | 2016-03-31 | 2018-12-06 | Univ Leuven Kath | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
WO2017167950A1 (en) | 2016-03-31 | 2017-10-05 | Janssen Pharmaceuticals, Inc. | Substituted indole derivatives as dengue viral replication inhibitors |
US10730884B2 (en) | 2016-04-01 | 2020-08-04 | Janssen Pharmaceuticals, Inc. | Substituted indole compound derivatives as dengue viral replication inhibitors |
JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
CN110062757B (zh) * | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
BR112019024311A2 (pt) | 2017-05-22 | 2020-07-28 | Janssen Pharmaceuticals, Inc. | derivados de indolina substituídos como inibidores da replicação viral do dengue |
WO2018215315A1 (en) | 2017-05-22 | 2018-11-29 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
CN114375290A (zh) * | 2019-04-11 | 2022-04-19 | 百时美施贵宝公司 | 制备(6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-氧代基-1(6h)-嘧啶基}-1-(二氧甲基)-6-甲基-1,4,7,8,9,10-六氢-11,15-(亚甲桥基)吡唑并[4,3-b][1,7]二氮杂环十四炔-5(6h)-酮的新颖合成选项 |
BR112021020257A2 (pt) * | 2019-04-11 | 2021-12-07 | Bristol Myers Squibb Co | Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico |
KR102709654B1 (ko) * | 2019-04-16 | 2024-09-26 | 차이나 리소어시즈 바이오파마슈티컬 컴퍼니 리미티드 | XIa 인자 억제제로서의 거대고리 유도체 |
JP7286001B2 (ja) * | 2019-07-23 | 2023-06-02 | メッドシャイン ディスカバリー インコーポレイテッド | 第XIa因子阻害剤としての大環状誘導体 |
BR112022005660A2 (pt) * | 2019-09-27 | 2022-07-12 | Shenzhen Salubris Pharm Co Ltd | Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos. |
BR112022020243A2 (pt) * | 2020-04-10 | 2022-11-22 | Bristol Myers Squibb Co | Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1,6-diidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15-tetraazatriclo[12,3,1,02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona |
TW202229280A (zh) * | 2020-10-12 | 2022-08-01 | 美商必治妥美雅史谷比公司 | (6r,10s)-10-{4-[5-氯-2-(4-氯-1h-1,2,3-三唑-1-基)苯基]-6-側氧基-1(6h)-嘧啶基}-1-(二氟甲基)-6-甲基-1,4,7,8,9,10-六氫-11,15-(亞甲橋基)吡唑并[4,3-b][1,7]二氮雜環十四炔-5(6h)-酮之製備方法 |
KR20230142724A (ko) | 2021-01-08 | 2023-10-11 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도 |
TW202246268A (zh) * | 2021-04-21 | 2022-12-01 | 大陸商上海美悦生物科技發展有限公司 | FXIa抑制劑及其藥物組合物、製備方法和用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
PE121699A1 (es) | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
CA2383008A1 (en) | 1999-06-14 | 2000-12-21 | Amanda Jane Lyons | Compounds |
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
RS20080517A (en) | 2001-09-21 | 2009-07-15 | Bristol-Myers Squibb Company, | Lactam containing compounds and derivatives thereof as factor xa inhibitors |
US20040180855A1 (en) | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
JP5841547B2 (ja) * | 2010-02-11 | 2016-01-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害剤としてのマクロ環 |
TW201311689A (zh) * | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
US9327839B2 (en) * | 2011-08-05 | 2016-05-03 | General Atomics | Method and apparatus for inhibiting formation of and/or removing ice from aircraft components |
SG11201403402VA (en) * | 2011-12-21 | 2015-01-29 | Ono Pharmaceutical Co | Compounds |
PL2880026T3 (pl) * | 2012-08-03 | 2017-08-31 | Bristol-Myers Squibb Company | Dihydropirydon P1 jako inhibitory czynnika XIA |
HUE031582T2 (en) | 2012-08-03 | 2017-07-28 | Bristol Myers Squibb Co | Dihydropyridone as xia factor inhibitors |
NO2760821T3 (he) * | 2014-01-31 | 2018-03-10 | ||
CN110845498B (zh) * | 2014-01-31 | 2023-02-17 | 百时美施贵宝公司 | 作为因子xia抑制剂的具有杂环p2′基团的大环化合物 |
NO2721243T3 (he) * | 2014-10-01 | 2018-10-20 |
-
2012
- 2012-06-14 NO NO12801069A patent/NO2721243T3/no unknown
-
2015
- 2015-07-29 TW TW104124664A patent/TWI692478B/zh active
- 2015-07-29 CN CN202210580097.2A patent/CN114957255A/zh active Pending
- 2015-07-29 MA MA40123A patent/MA40123A1/fr unknown
- 2015-07-29 MY MYPI2017701150A patent/MY183987A/en unknown
- 2015-07-29 KR KR1020177011233A patent/KR101921436B1/ko active IP Right Grant
- 2015-07-29 PT PT171899354T patent/PT3293186T/pt unknown
- 2015-07-29 TW TW109111475A patent/TWI769442B/zh active
- 2015-07-29 SG SG11201702576QA patent/SG11201702576QA/en unknown
- 2015-07-29 SG SG10201911652TA patent/SG10201911652TA/en unknown
- 2015-07-29 EP EP15747721.7A patent/EP3089979B1/en active Active
- 2015-07-29 SI SI201530123T patent/SI3089979T1/sl unknown
- 2015-07-29 ES ES15747721.7T patent/ES2655884T3/es active Active
- 2015-07-29 HU HUE17189935A patent/HUE052812T2/hu unknown
- 2015-07-29 PL PL15747721T patent/PL3089979T3/pl unknown
- 2015-07-29 MX MX2017003695A patent/MX2017003695A/es active IP Right Grant
- 2015-07-29 TW TW111120670A patent/TWI834182B/zh active
- 2015-07-29 EP EP17189935.4A patent/EP3293186B1/en active Active
- 2015-07-29 TN TN2017000112A patent/TN2017000112A1/en unknown
- 2015-07-29 LT LTEP15747721.7T patent/LT3089979T/lt unknown
- 2015-07-29 DK DK17189935.4T patent/DK3293186T3/da active
- 2015-07-29 CN CN201580053079.7A patent/CN106795161B/zh active Active
- 2015-07-29 EP EP23185426.6A patent/EP4286372A3/en active Pending
- 2015-07-29 DK DK15747721.7T patent/DK3089979T3/en active
- 2015-07-29 EP EP20197284.1A patent/EP3828186B1/en active Active
- 2015-07-29 CA CA2963395A patent/CA2963395C/en active Active
- 2015-07-29 UY UY0001036244A patent/UY36244A/es active IP Right Grant
- 2015-07-29 RS RS20180046A patent/RS56786B1/sr unknown
- 2015-07-29 JP JP2017517766A patent/JP6462865B2/ja active Active
- 2015-07-29 WO PCT/US2015/042576 patent/WO2016053455A1/en active Application Filing
- 2015-07-29 TN TNP/2018/000229A patent/TN2018000229A1/en unknown
- 2015-07-29 HU HUE15747721A patent/HUE038061T2/hu unknown
- 2015-07-29 PE PE2020001966A patent/PE20210922A1/es unknown
- 2015-07-29 ES ES17189935T patent/ES2836270T3/es active Active
- 2015-07-29 SI SI201531423T patent/SI3293186T1/sl unknown
- 2015-07-29 AU AU2015324530A patent/AU2015324530B2/en active Active
- 2015-07-29 PT PT157477217T patent/PT3089979T/pt unknown
- 2015-07-29 LT LTEP17189935.4T patent/LT3293186T/lt unknown
- 2015-07-29 RS RS20201472A patent/RS61183B1/sr unknown
- 2015-07-29 ES ES20197284T patent/ES2963267T3/es active Active
- 2015-07-29 PE PE2017000527A patent/PE20170939A1/es unknown
- 2015-07-29 EA EA201790595A patent/EA031590B1/ru not_active IP Right Cessation
- 2015-07-29 CN CN201910882473.1A patent/CN110734435B/zh active Active
- 2015-07-29 KR KR1020187033199A patent/KR102269999B1/ko active IP Right Grant
- 2015-07-29 AR ARP150102426A patent/AR101367A1/es active IP Right Grant
-
2017
- 2017-03-21 MX MX2020010840A patent/MX2020010840A/es unknown
- 2017-03-24 CL CL2017000712A patent/CL2017000712A1/es unknown
- 2017-03-28 IL IL251434A patent/IL251434B/he active IP Right Grant
- 2017-03-29 PH PH12017500580A patent/PH12017500580A1/en unknown
- 2017-04-07 ZA ZA2017/02478A patent/ZA201702478B/en unknown
- 2017-04-20 CO CONC2017/0003833A patent/CO2017003833A2/es unknown
- 2017-12-15 CY CY20171101314T patent/CY1119678T1/el unknown
- 2017-12-18 HR HRP20171950TT patent/HRP20171950T1/hr unknown
-
2018
- 2018-12-27 JP JP2018244086A patent/JP6937734B2/ja active Active
-
2020
- 2020-01-20 AU AU2020200376A patent/AU2020200376B2/en active Active
- 2020-01-27 PH PH12020500195A patent/PH12020500195A1/en unknown
- 2020-08-03 IL IL276470A patent/IL276470B/he active IP Right Grant
- 2020-12-03 HR HRP20201927TT patent/HRP20201927T1/hr unknown
- 2020-12-04 CY CY20201101149T patent/CY1123663T1/el unknown
-
2021
- 2021-08-31 JP JP2021140618A patent/JP7317905B2/ja active Active
- 2021-10-05 AU AU2021245098A patent/AU2021245098B2/en active Active
-
2023
- 2023-07-19 JP JP2023117409A patent/JP2023134734A/ja active Pending